Moderna’s COVID-19 Vaccine Sales Exceed Expectations, but RSV Vaccine Falls Short

COVID-19 Vaccine Success:
Moderna reported better-than-expected sales of its COVID-19 vaccine, Spikevax, with $1.8 billion in the third quarter, a 3.5% year-over-year growth.

RSV Vaccine Disappointment:
The company's RSV vaccine, mResvia, had a slow start with only $10 million in sales, significantly lower than the expected $64 million, due to late approval and limited market penetration.

RSV Vaccine Approval and Recommendations:
The FDA approved mResvia in May 2024 for adults 60 and older, but the CDC only recommends RSV vaccination for seniors aged 75 and older and those 60-74 at risk of severe disease.

Future Plans:
Moderna plans to file a regulatory submission for mResvia in high-risk adults 18-59 years old by the end of 2024 and is working on other vaccine projects, including a combination flu and COVID-19 vaccine.

Leadership Changes:
Moderna's CEO, Stéphane Bancel, will step back from his commercial role, with President Stephen Hoge taking over those duties.